1. [P3–055]: A PLATFORM FOR NOVEL IN VIVO MOLECULAR PROBES FOR ATTENUATION OF SYNAPTIC DYSFUNCTION AND PROINFLAMMATORY CYTOKINE OVERPRODUCTION. (1st July 2017) Authors: Van Eldik, Linda J.; Roy, Saktimayee M.; Arancio, Ottavio; Watterson, D Martin Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 19 Page Start: P951 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development of an orally bioavailable stress kinase inhibitor with brain exposure that targets the neuroinflammation‐synaptic dysfunction pathophysiology axis: Human/Human trials: Other. (7th December 2020) Authors: Watterson, Daniel Martin; Arancio, Ottavio; Windisch, Manfred; Pelletier, Jeffrey; Roy, Saktimayee M. Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. First‐in‐Human Studies of MW01‐6‐189WH, a Brain‐Penetrant, Antineuroinflammatory Small‐Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. Issue 2 (7th April 2020) Authors: Van Eldik, Linda J.; Sawaki, Lumy; Bowen, Karen; Laskowitz, Daniel T.; Noveck, Robert J.; Hauser, Byron; Jordan, Lynn; Spears, Tracy G.; Wu, Huali; Watt, Kevin; Raja, Shruti; Roy, Saktimayee M.; Watterson, D. Martin; Guptill, Jeffrey T. Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 2(2021) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. First‐in‐human studies of MW01‐6‐189WH, a brain‐penetrant, anti‐neuroinflammatory, small molecule drug candidate: Phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic studies in healthy adult volunteers: Human/Human trials: Inflammation. (7th December 2020) Authors: Van Eldik, Linda J.; Roy, Saktimayee M.; Guptill, Jeffrey T. Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1‐304: An optimized and isoform‐selective p38aMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. (1st July 2015) Authors: Van Eldik, Linda J.; Roy, Saktimayee M.; Watterson, D. Martin; Arancio, Ottavio Journal: Alzheimer's & dementia Issue: Volume 11(2015)Supplement 7:Part 10 Page Start: P473 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗